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http://dxObjectives: Patients may develop liver dysfunction, including liver fibrosis, over the long term following Fontan
procedure. Therefore, early detection of liver dysfunction is essential to identify those patients who are at risk.
We evaluated various laboratory parameters, including liver biochemical markers, hepatic echography findings,
and cardiac catheterization outcomes, at an early stage after undergoing Fontan procedure.
Methods: A total of 56 patients who underwent Fontan procedure were included in the study. All patients
underwent cardiac catheterization and biochemical markers were evaluated from the samples. Abdominal
echography was performed on a subgroup of patients (n ¼ 20) to observe the structure of liver tissues and to
measure blood flow in the hepatic vein, portal vein, and hepatic artery.
Results: The mean period of time since Fontan procedure was 2.8  2.1 years. There was a significant corre-
lation between venous pressure and serum levels of g-glutamyltranspeptidase and type IV collagen 7s domain,
which indicated a high probability of liver consolidation. The other biochemical markers were normal. Stepwise
regression analyses suggested that by using the ratio of hepatic venous flow and type IV collagen 7s collagen
domain concentration, inferior vena cava pressure can be predicted.
Conclusions: Our study showed that we can predict inferior vena cava pressure using noninvasive abdominal
echography and biochemical markers at an early stage after Fontan procedure. (J Thorac Cardiovasc Surg
2013;146:153-7)C
H
DSince 1971, the Fontan operation and its modifications have
been used for definitive palliation of patients with various
forms of functionally univentricular hearts.1 However, the
Fontan operation can result in various complications, includ-
ing central venous hypertension,2-4 depressed dynamic
cardiac output,3,5 and venous thrombosis.5,6 Liver
dysfunction over the long term following Fontan operation
has been suggested in several studies based on the findings
of liver function tests.2-7 Hepatic abnormalities, including
cholestasis, liver fibrosis, hepatomegaly, and liver cirrhosis,
may develop after the Fontan operation is performed. A
long-term increase in systemic venous pressure after the
Fontan procedure may cause abnormalities in liver function.
However, it is not known if progression of liver dysfunction
involves liver consolidation and changes in central venous
pressure in the short term after Fontan surgery, although it
is known that venous pressure increases immediately after
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The Journal of Thoracic and Cacollagen domain (7s collagen), which is involved in connec-
tive tissue metabolism, has been identified as a biochemical
marker for assessing liver consolidation.8 Further, several
other putative serummarkers, such as hyaluronic acid, aspar-
tate aminotransferase/platelet ratio index (APRI),9 and
FIB-4 score,10 either alone or in combination, have been
evaluated as liver fibrosis markers. The aims of our study
were to evaluate the relationship between the various nonin-
vasive liver function findings in the short term after Fontan
procedure and hemodynamic parameters from invasive cath-
eterization examination, and to identify the noninvasive pa-
rameters from echocardiography and/or laboratory data
that were significantly related to these invasive catheteriza-
tion variables.
METHODS
Between March 2007 and August 2011, the markers for hepatic fibrosis
were examined simultaneously in 58 consecutive patients undergoing cath-
eterization after Fontan procedure. Two cases were excluded because they
were emergency cases: in 1 case, partial occlusion in the conduit was sus-
pected, and the other casewas performed to detect lung bleeding; therefore,
56 patients were enrolled in this study.
This protocol was performed according to the guidelines of the Commit-
tee on Research of Kyoto Prefectural University ofMedicine, and informed
consent was obtained from all patients before their participation in the
study.
Laboratory Investigations
We included for analysis those variables that are assumed to be appro-
priate for assessing liver function based on synthesis, excretion, and hepa-
tocellular damage. Serum concentrations of total bilirubin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), alkalinerdiovascular Surgery c Volume 146, Number 1 153
Abbreviations and Acronyms
7s collagen ¼ type IV collagen 7s domain
APRI ¼ aspartate aminotransferase/platelet
ratio index
ALT ¼ alanine aminotransferase
AST ¼ aspartate aminotransferase
GGT ¼ g-glutamyltranspeptidase
IVCP ¼ inferior vena cava pressure
V1 ¼ peak velocity toward the conduit
V2 ¼ reverse flow toward the liver
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Dphosphatase, and g-glutamyltranspeptidase (GGT)were routinely obtained
at the start of intravenous drip for the anesthetization before catheteriza-
tion. Levels of 7s collagen and hyaluronic acid were measured as liver fi-
brosis markers. Measurement of 7s collagen domain was conducted by
SRL Inc (Tokyo, Japan), which offers clinical laboratory testing, and the
reference range (< 6.0 ng/mL) was defined by SRL Inc using data from
healthy control subjects. The APRI and Fibrosis-4 scores are simplified
scores of liver fibrosis and are calculated as follows: APRI ¼ (AST/upper
limit of normal)3 100/platelet count9; FIB-4¼ age (years)3AST (IU/L)/
[platelets (109/L) 3 ALT(IU/L)]1/2.10
Hemodynamic Assessment
At cardiac catheterization, conventional angiography and pressure mea-
surements were performed. We obtained pulmonary artery index scores ac-
cording to the method described by Nakata and colleagues.11Hepatic Echography and Doppler Studies
We performed abdominal echography for 20 patients using a Siemens
ultrasound system (Sequoia; Siemens, M€unich, Germany) equipped with
a 4.0 MHz transducer, and with patients in the supine position 1 day before
catheterization. Standard echographic imaging was performed from the
parasternal, apical, and subcostal windows for the evaluation of liver tis-
sues. Pulsed Doppler recordings of the right hepatic vein, right and left he-
patic arteries, and right portal vein were obtained with each patient
breathing quietly and in the supine position. We recorded 3 cycles from
each window at a sweep speed of 100 mm/second. Further, we calculated
the pulsatility ratio (minimal flow velocity:maximal flow velocity [normal
value>0.54]), of the portal vein as a marker of hepatic vein congestion,
and the resistance index (peak systolic velocity – end diastolic velocity/
peak systolic velocity [normal value<0.7]).12 The following parameters
were calculated using the hepatic vein flow velocity: peak velocity toward
the conduit (V1) and reverse flow toward the liver (V2) (Figure 1). From
these values, we calculated the ratio of hepatic vein flow (V2/V1).
Statistical Analysis
Statistical analysis was performed using JMP9 software (SAS Institute
Inc, Cary, NC). Nonparametric data were summarized the asmean, median,
standard deviation, and range. The Mann-Whitney U test was performed to
compare the groups. Correlations between variables were assessed using
Spearman’s r correlation coefficient. Subsequently, stepwise multiple lin-
ear regression was performed for multivariate analysis.
RESULTS
Baseline Clinical Characteristics
We enrolled 30 boys and 26 girls with a mean age of 4.8
 2.4 years (range, 2.6-13.2 years) (Table 1). The mean age154 The Journal of Thoracic and Cardiovascular Surgat the initial Fontan procedure was 2.0  1.3 years (range,
0.8-9.8 years). All patients had undergone an extracardiac
conduit Fontan procedure without fenestration. The mean
period of time since Fontan procedure was 2.8  2.1 years
(range, 0.6-11.0 years). No patient had active protein-losing
enteropathy at the time of assessment. Pacemaker implanta-
tion was documented in 1 patient.
Biochemical Profiles
The biochemical findings of liver function tests are sum-
marized in Table 1. Among the laboratory findings, only
GGT was mildly elevated. Liver cirrhosis and extensive fi-
brosis could be ruled out if the serum concentration of hya-
luronic acid was< 60 mg/L,13 and liver fibrosis could be
excluded if 7s collagen was<6.0 mg/L.14 Serum hyaluronic
acid levels were above normal in only 4 patients (7%), but
7s collagen was elevated in 35 patients (63%). An APRI
score> 1.5 indicates fibrosis9; however, no patients had
an APRI score> 1.5. The highest FIB-4 score in our pa-
tients was 0.44 (cutoff value>6.2),10 suggesting that no pa-
tients had extensive fibrosis. These results indicate that 7s
collagen and GGT are candidate markers of liver
dysfunction.
Hemodynamic Characteristics
The mean left and right ejection fractions were 64% 
7% and 55%  8%, respectively. Inferior vena cava
pressure (IVCP) ranged between 9 and 29 mm Hg (mean,
16  4 mm Hg). Serum brain natriuretic peptide
was<40 pg/mL in 52 patients (93%).
Univariate and Multivariate Analyses
Univariate analyses revealed a significant correlation be-
tween hemodynamic data and catheterization data (ie, be-
tween 7s collagen and IVCP, and between GGT and IVCP
[P<.05 for both]). There was no correlation between the
other liver biochemical markers (hyaluronic acid, APRI,
and Fibrosis-4 score) and any of the hemodynamic param-
eters. Multivariate analyses revealed a weak but significant
correlation only between IVCP and 7s collagen and GGT
(R2, 0.18; P ¼ .016). Patients with a 7s collagen> 6.0
ng/mL showed a high incidence of systemic venous pres-
sure (P<.01) (Figure 2). Hence, increased GGTand 7s col-
lagen could potentially indicate increased IVCP.
Hepatic Echography Results
With the exception of IVCP, there was no strong indicator
of liver dysfunction, such as brain natriuretic peptide or
other hemodynamic variables, including end-diastolic vol-
ume and ejection fraction, both of which were evaluated
by noninvasive examinations (ie, magnetic resonance imag-
ing or echocardiography). Therefore, we examined several
hepatic vessel flow patterns from the group of patients un-
dergoing echography (n ¼ 20) (Table 2). Compared withery c July 2013
FIGURE 1. A, Schematic of the pulsed Doppler recordings of hepatic
vein flow. B, Measurement of the pulsed Doppler recording of hepatic
vein flow in a patient who had undergone Fontan procedure (inferior
vena cava pressure ¼ 12 mm Hg). C, Measurement of the pulsed Doppler
recording of hepatic vein flow in a patient who had undergone Fontan pro-
cedure (inferior vena cava pressure¼ 25 mmHg). V1, Peak velocity toward
the conduit; V2, peak velocity of reversal wave toward the liver.
TABLE 1. Baseline characteristics of patients
Units
Mean
or n SD Median Range
Age (y) 4.8 2.4 3.7 2.6-13.2
Time since Fontan (y) 2.8 2.1 2.1 0.6-11.0
Sex (male/female) 30/26
Ventricle type
(right/left/both*)
28/24/4
Biochemistry
AST IU/L 40 11 40 12-65
ALT IU/L 21 8 20 6-40
GGT IU/L 65 48 56 18-328
T-bil mg/dL 0.76 0.3 0.69 0.3-1.76
Platelet 109/L 251 67 243 153-454
7s collagen ng/mL 6.8 1.7 7 3.6-14
Hyaluronic acid g/mL 25.1 20 18.5 8-85
APRI 0.48 0.16 0.45 0.16-0.90
FIB-4y 0.17 0.08 0.14 0.05-0.44
BNP pg/mL 27 50 13 4-276
Catheterization parameter
%EF
LV % 64 7 63 53-79
RV 55 8 55 36-70
%Volume
LV % 100 31 93 48-186
RV % 89 30 82 41-148
IVCP mm Hg 16 4 16 9-29
PA index mm2/m2 296 122 275 53-629
SD, Standard deviation; AST, aspartate aminotransferase; ALT, alanine aminotransfer-
ase; GGT, g-glutamyltranspeptidase, 7s collagen, type IV collagen 7s domain; APRI,
aspartate aminotransferase platelet ratio index; BNP, brain natriuretic peptide; EF,
ejection fraction; LV, left ventricle; RV, right ventricle; IVCP, inferior vena cava pres-
sure; PA, pulmonary artery. *2 criss-cross heart, 2 remote type double outlet RV.
yCalculated as age (y) 3 AST / [platelet 3 (ALT)]1/2.
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DV1 (Figure 1), the value of V2 was greater in patients with
higher IVCP. We thus expressed the ratio of hepatic venous
flow as V2/V1. In univariate analysis using hepatic echogra-
phy findings, we observed a significant correlation between
IVCP and the ratio of hepatic venous flow (P ¼ .028)
(Table 2). With the inclusion of sex and age at enrollment
for adjustment in the final models for echography and lab-
oratory investigations, stepwise regression analyses showed
that the ratio of hepatic venous flow and the 7s collagen con-
centration were strong predictors of IVCP
(IVCP ¼ 6.5 3 V2/V1 þ 0.95 3 7s collagen þ 4.9 [R2,
0.47; P<.01]).
DISCUSSION
Our results revealed liver function abnormalities in a ma-
jority of enrolled patients, even in those with a short interval
(mean, 2.8 years) since Fontan operation. In our study, 63%
of patients had abnormalities of 7s collagen. Univariate
analysis revealed that 7s collagen and GGT were weakly
but significantly correlated with central venous pressure.
Several investigators have reported that GGT increases sig-
nificantly after Fontan procedure.3,6 Moreover, total
bilirubin levels have been found to increase in the long
term in patients who undergo the Fontan operation.5 In
our study, total bilirubin did not increase in the short term
after Fontan surgery. Therefore, the serum levels of 7s col-
lagen and GGT can be considered the main abnormal find-
ings despite the difficulty in predicting IVCP using only
laboratory data (R2, 0.18). Thus, we added the other param-
eters using noninvasive methods.The Journal of Thoracic and CaHepatocellular tissue damage caused by hepatitis viral
infection and drugs, as well as other congenital anomalies,
can lead to liver function abnormalities. In Fontan circula-
tion, similar to chronic congestive heart failure,15 high pres-
sure in the central vein may lead to alterations of the hepatic
microvasculature, resulting in chronic centrilobular ische-
mia and chronic hypoxia. Simple scores (eg, APRI and
FIB-4), obtained from patients with hepatitis C virus and
alcoholic-induced cirrhosis, were normal because ALT
levels and platelets numbers were included in the formulae.
Histologic activity and fibrosis do not always correlate with
serum transaminase activity. Further, univariate or multivar-
iate analysis revealed that neither AST nor ALTactivity was
a risk factor, which is consistent with previous findings.3 It
is difficult to quantitatively assess hepatic functional re-
serve or completely determine the severity of chronic he-
patic injury or fibrosis based on standard liver blood tests.
The estimation of venous pressure is important; however,
central venous pressure is weakly correlated with 7s colla-
gen and GGT. We found that volume size and ejection frac-
tion, which can be measured by noninvasive magnetic
resonance imaging and echocardiography, could not berdiovascular Surgery c Volume 146, Number 1 155
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FIGURE 2. Individual values of inferior vena cava pressure (IVCP) in pa-
tients who had undergone Fontan procedure, according to type IV collagen
7s. *P<.01.
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Dused to predict the value of central venous pressure. There-
fore, we applied a series of hepatic blood flow measure-
ments using liver echography to identify a possible
relationship with central venous pressure. We evaluated
the relationship between 3 different flow ratios (those for
the portal vein, hepatic artery, and hepatic vein). Sherif
and colleagues16 reported that hepatic venous flow dynam-
ics are strongly related to the mean atrial pressure, and that
they can be used to estimate mean right atrial pressure. In
normal circulation, hepatic venous flow includes the sys-
tolic, diastolic, and atrial reversal wave velocities; that is,
it is triphasic. Determinants of systolic forward flow include
atrial relaxation, descent of the tricuspid annular plane to-
ward the ventricular apex, and right atrial pressure in the
normal circulation.16 In patients with chronic liver cirrho-
sis, hepatic vein waveforms are classified as monophasic,
biphasic, and triphasic (reversed flow in at least 1
phase).17,18 We evaluated the flow pattern of hepatic
venous flow and defined it as V1 or V2 (Figure 1). In patients
with liver dysfunction the values of these flow patterns dif-
fer from those of normal subjects. In comparison with V1
(Figure 1), the value of V2 was greater in patients with
higher IVCP. We accordingly defined the ratio of hepaticTABLE 2. Hepatic echography results
Mean or n SD Range P*
Evaluation of liver change 0 — — —
HV ratio 0.73 0.3 0.2-1.5 .028
PV ratio 0.64 0.12 0.38-0.78 .27
HA ratio 0.76 0.07 0.66-0.92 .13
SD, Standard deviation;HV, hepatic vein; PV, portal vein;HA, hepatic artery. *Signif-
icant variables in univariate test for association with inferior vena cava pressure.
156 The Journal of Thoracic and Cardiovascular Surgvenous flow as V2/V1. In both univariate and multivariate
analyses, we found a significant correlation between
IVCP and the ratio of hepatic venous flow, but found no cor-
relations between IVCP and the flow ratios for the hepatic
artery and portal vein flows, even though these are reported
to be useful for detecting hepatic venous congestion (Table
2). The change in the inferior vena cava diameter between
maximum on expiration and minimum on inspiration,
which is used frequently to estimate right atrial pressure
in normal circulation,17,19 was little in Fontan circulation.
Finally, we conclude that the IVCP in patients undergoing
Fontan procedure can be accurately predicted according
to the hepatic venous flow pattern and 7s collagen,
compared with using laboratory data only.
Ghaferi and colleagues20 reported that autopsy examina-
tion of liver specimens revealed marked changes in chronic
passive congestion in the liver histology more than 1 year
after the Fontan procedure was performed in 9 patients
with Fontan circulation. Although several serious complica-
tions such as hepatic adenoma and hepatocellular carci-
noma have been reported over the long term after the
Fontan procedure, using abdominal echography we could
not detect any pathologic evidence of liver fibrosis, such
as distention of sinusoids, dilatation of the portal area, or
nodular regeneration, in our study. This suggests that the de-
gree of liver congestion at an early stage after Fontan oper-
ation was not sufficiently severe to cause liver fibrosis.
It is important to evaluate the changes of coagulability
in patients who have undergone Fontan surgery. The prog-
ress of abnormal coagulability and advanced thrombus for-
mation in patients with Fontan circulation have been
reported.6 On the basis of this evidence, we performed an-
ticoagulation therapy at our institution. For this reason, we
excluded some of the simple indices of liver fibrosis, in-
cluding coagulation indices such as the cirrhosis discrimi-
nate score.21
Therapy that decreases pulmonary artery pressure and
central venous pressure may prevent the progression of liver
congestion in patients after the Fontan procedure is per-
formed. Further, antipulmonary hypertensive therapy may
affect the progress of liver dysfunction by decreasing the
end-diastolic pressure of the ventricle, thus avoiding exten-
sive hepatic investigations in patients with liver dysfunction
who are in heart failure. However, this approach has not
been used in the case of the Fontan procedure, and its effect
on Fontan circulation should be investigated.
CONCLUSIONS
Our study showed that serum levels of GGTand 7s colla-
gen are increased in those patients who have undergone
Fontan operation, and that these 2 indicators are signifi-
cantly correlated with systemic venous pressure. The he-
patic venous flow pattern was correlated only with
systemic venous pressure at an early stage after the Fontanery c July 2013
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Dprocedure was performed. Therefore, the monitoring of he-
patic venous flow and 7s collagen may be simple and effec-
tive methods for estimating systemic venous pressure and
the progress of liver dysfunction.
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